313 related articles for article (PubMed ID: 17467193)
1. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
[TBL] [Abstract][Full Text] [Related]
2. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
3. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
[TBL] [Abstract][Full Text] [Related]
4. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
[TBL] [Abstract][Full Text] [Related]
6. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
Chauvet B; Félix-Faure C; Davin JL; Berger C; Vincent P; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
9. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
10. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil.
Rödel C; Grabenbauer GG; Kühn R; Zörcher T; Papadopoulos T; Dunst J; Schrott KM; Sauer R
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1303-9. PubMed ID: 11955743
[TBL] [Abstract][Full Text] [Related]
11. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
14. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.
Wittlinger M; Rödel CM; Weiss C; Krause SF; Kühn R; Fietkau R; Sauer R; Ott OJ
Radiother Oncol; 2009 Nov; 93(2):358-63. PubMed ID: 19837472
[TBL] [Abstract][Full Text] [Related]
15. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
[TBL] [Abstract][Full Text] [Related]
17. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
[TBL] [Abstract][Full Text] [Related]
18. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
20. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
